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Background. In Sweden, social restrictions to contain
SARS-CoV-2 have primarily relied upon voluntary
adherence to a set of recommendations. Strict
lockdowns have not been enforced, potentially
affecting viral dissemination. To understand the
levels of past SARS-CoV-2 infection in the Stock-
holm population before the start of mass vaccina-
tions, healthy blood donors and pregnant women
(n = 5,100) were sampled at random between 14
March 2020 and 28 February 2021.
Methods. In this cross-sectional prospective study,
otherwise-healthy blood donors (n = 2,600) and
pregnant women (n = 2,500) were sampled for
consecutive weeks (at four intervals) throughout
the study period. Sera from all participants and a
cohort of historical (negative) controls (n = 595)
were screened for IgG responses against stabilized
trimers of the SARS-CoV-2 spike (S) glycoprotein
and the smaller receptor-binding domain (RBD). As
a complement to standard analytical approaches, a
probabilistic (cut-off independent) Bayesian frame-
work that assigns likelihood of past infection was
used to analyse data over time.
Setting. Healthy participant samples were randomly
selected from their respective pools through
Karolinska University Hospital. The study was
carried out in accordance with Swedish Ethical
Review Authority: registration number 2020–
01807.
Participants. No participants were symptomatic at
sampling, and blood donors were all over the age of
18. No additional metadata were available from the
participants.
Results. Blood donors and pregnant women showed a
similar seroprevalence. After a steep rise at the start
of the pandemic, the seroprevalence trajectory
increased steadily in approach to the winter second
wave of infections, approaching 15% of all individ-
uals surveyed by 13 December 2020. By the end of
February 2021, 19% of the population tested
seropositive. Notably, 96% of seropositive healthy
donors screened (n = 56) developed neutralizing
antibody responses at titres comparable to or higher
than those observed in clinical trials of SARS-CoV-2
spike mRNA vaccination, supporting that mild
infection engenders a competent B-cell response.
Conclusions. These data indicate that in the first year
since the start of community transmission,
seropositivity levels in metropolitan in Stockholm
had reached approximately one in five persons,
providing important baseline seroprevalence infor-
mation prior to the start of vaccination.
Keywords: antibody testing, COVID-19, population
immunity, SARS-CoV-2, serology, seroprevalence,
Sweden.
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Introduction
Densely populated areas – such as the Stockholm
region of 2.37 million people (975,000 within city
limits) – have facilitated the spread of SARS-CoV-2.
Evidence suggests that transmission can be cur-
tailed by imposing restrictions on leisure and
business activities, as well as by mask usage and
contact tracing [1-4]. In contrast to most compa-
rable countries, Sweden has favoured a strategy in
which individuals are encouraged to adhere to a set
of basic public health recommendations, while
society has remained largely open. Only recently –
faced with a winter second wave – did the govern-
ment opt for earlier closing hours for some busi-
nesses. The country has reported a significantly
higher burden on the public healthcare system to
date than its Scandinavian neighbours (Fig. 1a),
and there are many reasons for why this might be
the case.
Serological enumeration of past infections is crit-
ical for estimating viral spread and understanding
characteristics of the adaptive immune response to
an emerging pathogen [5]. Antibody testing is also
important for optimal planning of vaccination
campaigns (especially when doses are limited)
and could help demonstrate ‘immunity’ on official
documentation. However, as illustrated by the
current pandemic, not all antibody tests are of
equal sensitivity and specificity (S&S), and closer
scrutiny of assays is needed to improve public
health measures and our understanding of COVID-
19 [6].
To monitor seropositivity in the Stockholm region,
we developed highly sensitive and specific SARS-
CoV-2 antibody tests based on the native-like
spike glycoprotein [7] (alongside a diagnostic
clinical laboratory responsible for monitoring
seropositivity during the pandemic [8]), as well
as novel cut-off-independent statistical methods,
and applied them to random, healthy adults in
the region throughout 2020 and early 2021. Such
approaches, which improve upon strictly thresh-
olding a continuous variable, are critical for
accurate seropositivity estimates at individual
and population levels. This is especially impor-
tant in the case of SARS-CoV-2, as asymp-
tomatic/mild infections generate antibody
responses of varying titres that can be difficult
to classify [8-11], and the knowledge that indi-
vidual titres generally wane from peak levels over
time [12-15].
We chose to survey anti-S IgG responses as these
are the best indicators of past SARS-CoV-2 infec-
tion at the population level (i.e. present in >91% of
PCR-positive cases) [16,17]. Spike harbours the
ACE2 receptor-binding domain (RBD) and is the
major target of the neutralizing antibody response,
central to vaccine efforts. For example, anti-
nucleocapsid (N) antibodies were not detectable in
a subset of S-seropositive individuals [8,18-20].
For both S, N and RBD, the levels of antibodies in
circulation were shown to increase with worsening
disease severity [9,11,21], as also reported for
SARS-CoV and MERS [22,23].
Blood donors and pregnant women, studied here,
are important clinical groups, and pregnant women
require further study in relation to infectious dis-
ease [24,25]. Moreover, both groups represent good
and accessible proxies for adult population health,
being generally working age, mobile members of
society – without being enriched for individuals at
especially high-risk of SARS-CoV-2 infection, such
as healthcare workers or public transportation
employees, where seroprevalence may be higher
[26]. Similarly, seroprevalence may be higher in
children and lower in the elderly –with complemen-
tary studies much needed.
All healthy individuals in this study (n = 5,100)
were over the age of 18 and symptom-free at
sample collection. For ethical reasons, their ages
and genders are not revealed, nor is it known
whether any participant previously tested positive
for the virus. Thus, while we here provide an
unbiased assessment of past SARS-CoV-2 infec-
tion in two important groups in Stockholm in
response to natural infection and before the start
of mass adult vaccinations, future studies in other
cohorts are needed to generate more integrated
data to guide public health strategies.
Materials and methods
Human samples and ethical declaration
Anonymized samples (n = 5,100 total) from blood
donors (n = 100/sampling week) and pregnant
women (n = 100/sampling week) were randomly
selected from their respective pools through the
Department of Clinical Microbiology, Karolinska
University Hospital (KUH). During 2020, 18,963
pregnant women were under the care of KUH,
averaging 365 per week, of which 100 (~30%) were
selected at random from each sampling week.
Blood donations totalled 66,596 during 2020,
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Fig. 1 SARS-CoV-2 seropositivity estimates in Stockholm: March 2020–February 2021. (a) Population-adjusted COVID-19
deaths for selected countries during the pandemic. (b) Anti-S IgG responses in blood donors (BD), pregnant women (PW) and
n = 595 historical control (C) sera. 100 BD and 100 PW samples were analysed per sampling week alongside negative
controls (cut-out plot red points). Conventional 3 and 6 SD (from the mean of negative control values) assay cut-offs are
shown as dashed and solid lines, respectively. (c) Anti-RBD IgG responses in BD, PW and n = 595 historical control sera
(cut-out plot green points). Conventional 3 and 6 SD assay cut-offs are shown as dashed and solid lines, respectively
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averaging 1,281 per week and here weekly sam-
pling approximated 8% of the pool. No study
participant was analysed more than once over the
course of the study. Blood donor and pregnant
women samples were not collected during weeks
26–29, 35–45 and 51–53 of 2020 and 1–3 of 2021
for logistical reasons. Samples were collected from
26 weeks out of the 47 weeks the study ran. Blood
donors (n = 595) collected through the same chan-
nels one year previously (Spring 2019) were ran-
domly selected for use as assay negative serum
controls.
No metadata, such as age or sex information, were
available for the samples in the study. Blood
donors must be over 50 kg and over the age of
18, while no upper age limit is established in
Stockholm. Pregnant women were sampled as part
of routine screening for infectious diseases during
the first trimester of pregnancy. Whether a study
participant had previously tested positive for
SARS-CoV-2 PCR is unknown. Blood donors are
required to be healthy for a minimum of two weeks
before a donation and all participants reported
symptom-free at sample collection. We cannot
exclude that a very small number of blood donor
samples from 2021 were from individuals who had
received a COVID-19 vaccine. Healthcare workers
in the region were receiving first doses at the time
of writing, along with elderly persons; however,
mass vaccinations of adults (including pregnant
women) had not yet begun [27,28].
The use of study samples was approved by the
Swedish Ethical Review Authority (registration no.
2020–01807). Covid-19 mortality data for Sweden
was sourced from the European Centre for Disease
Control and Prevention (European Union) (https://
www.ecdc.europa.eu/en/covid-19/data) and were
current at the time of publication.
Serum sample processing
Blood samples were collected by the attending
clinical team and serum isolated by the Depart-
ment of Clinical Microbiology. Samples were anon-
ymized, barcoded and stored at 20°C until use.
Serum samples were not heat-inactivated for
ELISA protocols.
SARS-CoV-2 antigen generation
The plasmid for expression of the SARS-CoV-2
prefusion-stabilized spike ectodomain with a C-
terminal T4 fibritin trimerization motif was
obtained from Wrapp et al and produced as in
Hanke et al [29]. Briefly, the plasmid was used to
transiently transfect FreeStyle 293F cells using
FreeStyle MAX reagent (Thermo Fisher Scientific).
The ectodomain was purified from filtered super-
natant on Streptactin XT resin (IBA Lifesciences),
followed by size-exclusion chromatography on a
Superdex 200 in 5 mM Tris pH 8, 200 mM NaCl.
The RBD domain (RVQ–QFG) of SARS-CoV-2 was
cloned upstream of a sortase A recognition site
(LPETG) and a 6xHIS tag and expressed in 293F
cells as described above. RBD-HIS was purified
from filtered supernatant on His-Pur Ni-NTA resin
(Thermo Fisher Scientific), followed by size-
exclusion chromatography on a Superdex 200.
Anti-SARS-CoV-2 ELISA
96-well ELISA plates (Nunc MaxiSorp) were coated
with freshly prepared SARS-CoV-2 S trimers or the
RBD (100 µl of 1 ng/µl) in PBS for 15 h at 4°C.
Plates were washed six times with PBS–Tween-20
(0.05%) and blocked using PBS-5% no-fat milk
(Sigma). Human serum samples were thawed at
room temperature, diluted, vortexed and incubated
in blocking buffer for 1 h (4°C) before plating to
block non-specific binding. Serum samples were
incubated for 15 h at 4°C to allow low-affinity
binding interactions, before washing as before.
Secondary HRP-conjugated anti-human antibodies
were diluted in blocking buffer and incubated with
samples for 1 hour at 4°C. Plates were washed a
final time before development with TMB Stabilized
Chromogen kept at 4°C (Invitrogen). The reaction
was stopped using 1 M sulphuric acid and optical
density (OD) values were measured at 450 nm
using an Asys Expert 96 ELISA reader (Biochrom
Ltd.). Secondary antibodies (from Southern Bio-
tech) and dilutions used were as follows: goat anti-
human IgG (2014-05) at 1:10,000. All assays were
developed for their fixed time, and negative control
samples were run alongside test samples in all
assays. Anti-SARS-CoV-2 S and RBD IgG were
detectable at up to 1:20,000 serum dilution using
this assay [8], and all study samples were here run
at 1:100 dilution.
In vitro virus neutralization assay
Pseudotyped viruses were generated by the co-
transfection of HEK293T cells with plasmids
encoding the SARS-CoV-2 spike protein harbour-
ing an 18 amino acid truncation of the cytoplasmic
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tail; a plasmid encoding firefly luciferase; a lentivi-
ral packaging plasmid (Addgene 8455) using Lipo-
fectamine 3000 (Invitrogen). Media was changed
12–16 hours post-transfection and pseudotyped
viruses harvested at 48 and 72 hours, filtered
through a 0.45-µm filter and stored at 80°C until
use. Pseudotyped neutralization assays were
adapted from protocols validated to characterize
the neutralization of HIV, but with the use of ACE2-
expressing HEK293T cells. Briefly, pseudotyped
viruses sufficient to generate ~100,000 RLUs were
incubated with serial dilutions of heat-inactivated
serum for 60 min at 37°C. Approximately 15,000
HEK293T-ACE2 cells were then added to each well
and the plates incubated at 37°C for 48 hours.
Luminescence was measured using Bright-Glo
(Promega) according to the manufacturer’s instruc-
tions on a GM-2000 luminometer (Promega) with
an integration time of 0.3s. The neutralization
assay limit of detection was at 1:45 serum dilution.
Probabilistic seroprevalence estimations
Prior to analysis, each sample OD was log-
transformed and standardized by dividing by the
mean OD of ‘no sample control’ wells on that plate
or other plates run on the same day – to reduce
batch variation. This resulted in more similar
distributions for 2019 blood donor samples with
2020 blood donors and pregnant volunteers. Our
Bayesian approach is presented in detail in Chris-
tian and Murrell [30]. Briefly, we used a logistic
regression over anti-RBD and anti-S training data
(n = 595 historical blood donor controls and
n = 138 SARS-CoV-2 PCR+ individuals across the
clinical spectrum – all of whom developed anti-S
IgG and 97% did so against the RBD) to model the
relationship between the ELISA measurements and
the probability that a sample is antibody-positive.
We adjusted for the training data class proportions
and used these adjusted probabilities to inform the
seroprevalence estimates for each time point.
Given that the population seroprevalence cannot
increase dramatically from one week to the next,
we constructed a prior over seroprevalence trajec-
tories using a transformed Gaussian Process and
combined this with the individual class-balance
adjusted infection probabilities for each donor to
infer the posterior distribution over seroprevalence
trajectories. We compared our Bayesian approach
to the output of more established probabilistic
algorithms (specifically, an ensemble learner from
support vector machines (SVM) and linear
discriminant analysis (LDA) – SVM-LDA) that we
have previously developed for ELISA measure-
ments.
The sensitivity and specificity (S&S) of our IgG
ELISA assays were as follows:
• Spike 3SD:100% (95% CI [97.5–100.0]) & 99.0%
(95% CI [98.6–99.0])
• Spike 6SD:100% (95% CI [97.5–100.0]) & 99.9%
(95% CI [99.6–100.0])
• RBD 3SD:100% (95% CI [97.5–100.0]) & 99.0%
(95% CI [98.4–99.4])
• RBD 6SD:98.0% (95% CI [94.2–99.3]) & 99.9%
(95% CI [99.6–100.0])
• SVM-LDA:99.3% (95% CI [96.3–100.0) & 100.0%
(95% CI [99.8–100.0])
To compute confidence intervals for S&S, we
dichotomized predictions of seropositivity at prob
> 0.5 or <= 0.5 and computed average sensitivity,
specificity and 95% confidence intervals for each
fold in the cross-validation via Wilson’s method
before averaging over all folds. The Bayesian model
does not make assignments of seropositivity to
individual samples, but rather integrates over the
uncertainty in relationship between infection and
OD450, as well as the uncertainty due to sampling,
to provide population-level seroprevalence esti-
mates. Thus, S&S cannot be calculated for this
approach.
Results
Blood donor (BD) and pregnant women (PW) serum
samples (n = 100 of each per sampling week) were
selected at random from their respective pools and
the IgG response against SARS- CoV-2 S glycopro-
tein trimers and the smaller RBD subunit was
measured in all sera using established ELISA
assays extensively validated using sera from con-
firmed infections [8] (Fig. 1b,c); anti-S and RBD
responses are highly correlated, with lower titres
generally observed for the smaller RBD.
Test samples were run alongside historical (SARS-
CoV-2-negative) control sera (n = 595 blood donors
from spring 2019) over the course of the study.
Seropositivity for S and RBD according to conven-
tional 3 or 6 standard deviations (SD) (from the
mean of negative control sera) assay cut-offs is
presented in Table 1 and Fig. 2a. Notably, seropos-
itivity was not significantly different between blood
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donors and pregnant women over the study period
(Fig. 2b,c).
However, the many measurements between the 3
and 6 SD cut-offs for both or a single antigen
(Fig. 1b,c) pose a problem when assigning case to
low values, uncertainty that can significantly skew
seroprevalence estimates and is undesirable at the
individual level. Therefore, to provide an accurate
seropositivity estimate for our population and to
model seropositivity changes over time, we
developed a cut-off-independent, probabilistic
Bayesian framework that models the log odds that
a sample is antibody-positive based on anti-S and
anti-RBD IgG responses in training data, in this
case SARS-CoV-2 PCR+ COVID-19 patients
(n = 136) across the clinical spectrum (including
asymptomatic/mild cases) [8].
Using this more quantitative approach that better
considers the wide range of responses present in
the population and shares information between
Table 1 IgG seropositivity to S and RBD in blood donors and pregnant women following virus emergence
Weeks 2020–2021 Bayesian estimate S IgG (3SD) RBD IgG (3SD) S IgG (6SD) RBD IgG (6SD)
2020
14: 30 March—5 April 2.4 2.5 0.5 0.5 0.5
Sampling gap
17: 20–27 April 4.8 6.0 5.0 4.5 4.0
18: 27 April–3 May 5.4 8.0 5.0 5.0 4.0
19: 4–10 May 5.9 11.5 8.0 9.0 8.0
20: 11–17 May 6.3 8.0 9.0 7.0 8.0
21: 18–24 May 6.7 12.0 10.0 8.0 7.5
22: May 25–31 May 7.0 4.5 3.5 4.0 3.5
23: 1–7 June 7.3 10.5 9.0 9.5 7.0
24: 8–14 June 7.8 8.0 8.0 6.5 7.0
25: 15–21 June 8.3 8.5 7.0 7.5 7.0
Sampling gap
30: 20–26 July 11.4 22.0 20.5 17.0 14.5
31: 27 July–2 August 11.9 14.5 13.5 10.5 9.0
32: 3–9 August 12.3 18.0 16.0 13.5 10.5
33: 10–16 August 12.5 15.5 12.5 12.5 10.0
34: 17–23 August 12.7 20.0 20.0 16.5 9.5
Sampling gap
45: 2–8 November 14.1 15.5 14.0 12.5 11.0
46: 9–15 November 14.2 21.0 17.0 16.5 13.5
47: 16–22 November 14.3 17.5 16.0 17.0 12.0
48: 23–29 November 14.5 20.5 18.0 16.0 12.5
49: 30 November–6 December 14.7 16.5 14.5 12.5 12.0
50: 7–13 December 14.8 20.0 17.5 18.0 15.5
2021 Sampling gap
4: 25–31 January 18.2 28.5 22.0 23.5 15.0
5: 1–7 February 18.5 23.5 23.0 21.5 13.0
6: 8–14 February 18.8 25.5 19.5 19.0 15.5
7: 15–21 February 19.0 28.5 25.0 25.5 16.5
8: 22–28 February 19.2 29.5 26.0 25.5 16.5
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sampling weeks, we found seropositivity to
increase sharply at the start of the pandemic
(Fig. 2d). By the time, the COVID-19 death rate in
the country was at low levels during August,
following the first wave, the seroprevalence trajec-
tory increased at a steady, but slower rate in
approach to the winter second wave (Fig. 2d) – in
agreement with continued viral spread in the
Stockholm population during a summer recess in
cases and mortality, and consistent with persistent
individual antibody responses over a 9-month
period [31].
By week 50 (13 December 2020), our probabilistic
approach identified 14.8% (95% Bayesian CI [12.2–
18.0]) of the cohort to have been previously infected
(a)
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Fig. 2 SARS-CoV-2 seropositivity estimates in Stockholm: March 2020–February 2021. (a) Seropositivity estimates in BD
and PW combined, according to 3 and 6 SD assay cut-offs. (b) Spike seropositivity in BD and PW according to 3 and 6 SD
assay cut-offs. (c) RBD seropositivity in BD and PW according to 3 and 6 SD assay cut-offs. (d) Cut-off-independent
Bayesian modelling of population seropositivity. (e) In vitro pseudotyped virus neutralizing titres in a subset (n=56) of
antibody-positive BD and PW. Bars represent the geometric mean. (f) Binding and neutralization – for samples in (e) – are
highly correlated
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(Table 1 and Table S1). The seroprevalence level
again increased more rapidly between mid-
December and the end of February 2021, consis-
tent with the winter peak in mortality and infec-
tions, and reached 19.2% (95% Bayesian CI [15.1–
24.4]) of the population by last sampling. Thus,
approximately one in five healthy adults in Stock-
holm showed evidence of past natural SARS-CoV-2
infection before the start of mass adult vaccina-
tions in the country. An equal-weighted probabilis-
tic SVM-LDA learner that we had previously
optimized for ELISA measurements showed highly
consistent results (Table S2).
Importantly, 96% of seropositive blood donors and
pregnant women randomly subsampled (n = 56
from March to May 2020) had virus-neutralizing
responses in their sera (ID50=600; 95% CI [357 –
1,010] and ID50=350; 95% CI [228–538], respec-
tively, Fig. 2e,f), with titres comparable to those
engendered by recently approved COVID-19 mRNA
vaccines that were shown to be protective in
clinical phase 3 trials [32,33]. These observations
support that asymptomatic/mild infection gener-
ates an antibody response that provides a degree of
protection upon re-exposure, although inter-
individual heterogeneity, environmental factors
and different SARS-CoV-2 variants will play a role
in individual outcomes.
Discussion
To characterize immunological responses to SARS-
CoV-2 and safeguard public health, it is critical to
monitor the level of population immunity after
natural infection, especially in settings with differ-
ent public health measures – allowing for concur-
rent and retroactive evaluation of different
strategies. As Sweden has taken a unique public
health approach to mitigate the effects of the virus,
data from the country provide an important con-
trast to comparable settings.
Serology is amenable to studies of large cohorts
and remains the gold standard for determining
previous exposure to pathogens. Several studies
have highlighted the protective role antibodies play
in controlling SARS-CoV-2 infection in humans
[34,35] and animal models [36,37], and potent
neutralizing and convergent antibodies were
rapidly isolated from infected donor samples [38-
40]. Indeed, mounting evidence suggests that most
persons (>91%) previously infected with SARS-
CoV-2 develop virus-specific antibodies, including
following mild infections [8,16,17,31]. Critical
ongoing and future research is required to deter-
mine the duration of serological responses and B-
cell memory in those infected, as well as following
vaccination.
Early research has shown that the majority of
mildly infected individuals maintain detectable
virus-specific B-cell responses for at least 8–
10 months [17,31]. Together with the steadily
increasing seropositivity observed in this study
and elsewhere, such as New York City [41], these
findings help allay early concerns that immunity
waned in the short term, although individuals with
mild infection can have antibody titres close to the
assay boundary. Data suggest that ~10% of SARS-
CoV-2 seropositive individuals can lose detectable
titres 10 months post-PCR test [12,15,17],
although this proportion remains to be reported
in larger and different cohorts. Therefore, the levels
of past infection in this cohort may be slightly
higher than we report. Anti-SARS-CoV antibodies
have been reported to persist for 3 years following
more severe infection [42,43], while detectable
responses to seasonal coronaviruses generally
wane within 1–2 years and immunity is affected
by rhythms in their circulation [44-46]. Impor-
tantly, as the activated B-cell pool and antibody
response contracts following viral clearance (and
declines in function with age [47,48]), the identifi-
cation of low but persistent antibody responses
(that may be highly effective) remains a challenge
using conventional serological methods.
Notably, we observed virus-neutralizing titres in
our cohorts to be comparable to those engendered
by the first mRNA vaccines of Pfizer/BioNTech [33]
and Moderna [34], supporting that natural infec-
tion generates neutralizing immunity to the infec-
tious strain, as do studies of healthcare workers
[35] and elderly care home residents and staff [49],
in whom re-infection rates were substantially
reduced. The potential endemicity and continued
evolution of SARS-CoV-2 may alter the nature of
protective immunity (e.g. possible re-infection with
a different strain), and knowledge of strain-specific
antibody responses should be used to optimally
coordinate vaccine interventions and inform public
health measures.
Epidemiologically, our data indicate that approxi-
mately one year since virus emergence in Sweden,
approximately one in five adults in the categories
studied here (blood donors and pregnant women)
Stockholm SARS-CoV-2 seroprevalence after natural infection / X. Castro Dopico et al.
8 ª 2021 The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine
Journal of Internal Medicine
in Stockholm had been previously infected by the
virus. The situation in Stockholm is like that
observed in New York City, USA, where despite
high rates of infection and mortality [50], herd
immunity was not attained within six months of
the outbreak, with seropositivity reaching ~20% of
the general adult population [41]. Despite an
estimated >60% IgG seroprevalence after the first
wave [51], Manaus, Brazil, was also not spared a
severe second wave of infections [52]. As SARS-
CoV-2 variants continue to emerge [53], seropreva-
lence measurements reported from many countries
highlight a continued need to curtail viral trans-
mission through social restrictions and effective
vaccination programmes.
Our study supports that Stockholm has suffered a
higher number of infections (following the first
wave) than most European locations studied [54-
59], in agreement with high per capita mortality.
However, direct comparisons between sites are
complicated by differences in the demographics of
the study subjects as well as the S&S of the assay
used for antibody detectiony [60]. Longitudinal
studies over longer timescales and in different
cohorts are urgently needed for improved under-
standing of population immune responses after
SARS-CoV-2 infection and COVID-19 vaccination.
Conclusions
These data highlight a relatively high SARS-CoV-2
seroprevalence in Stockholm, Sweden, following
one year of community transmission. Population
serology informs disease epidemiology and public
health approaches and can help target vaccines
where they are most efficacious.
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